Terumo Cardiovascular Group to Distribute Nonin Medical’s SenSmart™ Model X-100 Universal Oximetry System in U.S. Cardiovascular Hospitals
Terumo Cardiovascular Group today announced that, beginning immediately, it will distribute Nonin Medical’s SenSmart™ Model X-100 Universal Oximetry System to adult and pediatric cardiovascular hospitals in the United States. This is an expansion of the distribution agreement between Terumo and Nonin, which was originally entered into on May 1, 2013.
The Nonin SenSmart Universal Oximetry System is the first dedicated oximeter system that provides measurements of both regional oximetry (rSO2) and pulse oximetry (SpO2). The SenSmart system provides comprehensive monitoring of up to six-channels of rSO2 and SpO2 in an innovative side by side view. No other oximeter system provides more than four channels of monitoring. The signal processor is substantially smaller than previous versions, making the SenSmart system ideal for use in a variety of settings where space is an issue, such as the CVOR or ICU. The system allows anesthesiologists, perfusionists, cardiovascular surgeons and other clinicians to quickly identify tissue ischemia events before they become critical.
"We're excited to offer this next-generation monitoring device to our customers, particularly because the new features and upgrades are the direct result of customer feedback on the Nonin EQUANOX™ Model 7600 Regional Oximetry System," said Carol Koch, Senior Product Manager, Cardiovascular Monitoring. "Customers said they wanted features like an easier to use interface, color-coded and site-labelled display and smaller signal processors. The result is the SenSmart Model X-100 Universal Oximetry System, an intuitive and easy to use device that delivers both pulse and regional oximetry measurements today, and is designed to accommodate more parameters in the future."
Advantages of the SenSmart™ Model X-100 Universal Oximetry System include:
- Highly Accurate –The SenSmart System’s EQUANOX Advance rSO2 Sensors provide clinicians with state-of-the-art accuracy. Nonin’s reusable SpO2 Soft Sensors provide fast, accurate and reliable readings even in patients with low perfusion or in the presence of motion.
- Versatile – Provides the ability to use any combination of Nonin SenSmart-compatible rSO2 sensors and/or SpO2sensors to monitor up to six sites on a patient.
- Easy to Use – The smaller, lighter and less-intrusive SenSmart Universal Signal Processors automatically recognize and display either the rSO2 or SpO2 signal, as well as the channel number you have chosen to connect to.
- Convenient – The portable, easy-to-operate SenSmart Monitor offers Bluetooth® wireless or RS232 case download connectivity, as well as connectivity with Philips® IntelliVue® Monitors via VueLink® or IntelliBridge®interface.
For more information about the Nonin SenSmart™ Model X-100 Universal Oximetry System, visit www.terumo-cvgroup.com/universaloximetry.
Nonin Medical, Inc. invented the finger pulse oximeter (the original Onyx® brand) and designs and manufactures noninvasive medical monitoring solutions that meet customers’ technology needs today and tomorrow. Headquartered in Plymouth, Minn., USA, with an additional customer service center in Amsterdam, the Netherlands, Nonin Medical sells its pulse and regional oximeters, capnographs, sensors and software to health professionals and consumers in more than 125 countries. The company has more than 300 OEM partners worldwide. For more information, visit nonin.com.
About Terumo Cardiovascular Group
Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit www.terumo-cvgroup.com.
About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.